PI3K | GenomeWeb


Using an algorithm known as HotNet2, an international team has identified more than a dozen genetically altered sub-networks in thousands of tumor samples assessed for the Cancer Genome Atlas project.

Early data presented at SABCS suggests that ER/PR-positive breast cancer patients could respond particularly well to Genentech's PI3 kinase inhibitor.

Researchers from the Dana Farber Cancer Institute have published results of a preliminary study tracking the patterns of mutations in the two histological subtypes of cervical cancer, which they are now planning to put to the test in a clinical trial of PI3 kinase inhibitors.

Sharing a co-exclusive license to PI3K with Qiagen, Roche will develop assays for diagnostic markers to help subsidiary Genentech and external pharma partners to advance investigational drug candidates that inhibit PI3K.

Roche announced this week that the co-exclusive license for the biomarker would allow it to develop real-time and endpoint PCR assays to detect mutations in the PI3K oncogene, which would aid its subsidiary Genentech in the development of several investigational drug candidates.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.